The company expects to recruit around 500 patients at 15 sites in China.
Boston Scienific received CE Mark approval for the Promus Element Everolimus-Eluting Stent System in October 2009 and for the TAXUS Element Paclitaxel-Eluting Stent System in May 2010.
Boston Scientific Cardiology, Cardiology Rhythm and Vascular Group senior vice president and chief medical officer said the Element Stent series has been well received by physicians in CE Mark countries, and we look forward to bringing this advanced coronary stenting technology to Chinese physicians and their patients.
Boston Scientific Cardiology Rhythm and Vascular executive vice president and group president Hank Kucheman said the advanced platinum chromium alloy and new balloon catheter offered in the Element Stent System represent significant improvements over prior-generation stents.